


EARN  
**1.5**  
CME CREDITS

A **CME JEOPARDY** ACTIVITY

# CAN YOU MASTER MASH DIAGNOSIS AND MANAGEMENT?



**SATURDAY  
MAY 3, 2025**

**6:00 PM – 8:00 PM**

Educational Session: 6:30 PM – 8:00 PM

Manchester Grand Hyatt • Grand Hall A, Ground Level

 **DINNER WILL BE PROVIDED.**



JOIN IN-PERSON OR ONLINE  
**REGISTER  
NOW!**

[ExchangeCME.com/group-events/MASHSanDiego](https://ExchangeCME.com/group-events/MASHSanDiego)

## PROGRAM OVERVIEW

With the recent change in terminology to metabolic dysfunction–associated steatotic liver disease (MASLD) and MASH and the new cardiometabolic criteria, clinical practice has shifted to incorporate screening of more patients for MASLD/MASH. Employing NITs is essential to identifying patients at high risk for MASH and further disease progression, as well as for selecting patients for the first-ever approved MASH therapy, resmetirom. Cardiometabolic comorbidities are common in these patients, and clinicians must be prepared to manage them, often using GLP-1 RAs. After a didactic background on MASH, attendees will compete in a *CME Jeopardy* game. Teams will be led by Drs. Mazen Nouredin and Kimberly Watt and the game will be moderated by Dr. Sonal Kumar. Topics covered will include nuances of diagnosis and staging using NITs, selecting candidates for resmetirom, and optimal management strategies, such as GLP-1 RAs, for the management of common cardiometabolic comorbidities. **Join us for this fun, exciting, and competitive program and see if you have what it takes to win!**



**SONAL  
KUMAR, MD, MPH**

*Weill Cornell Medicine  
New York, New York*



**MAZEN  
NOUREDDIN, MD, MHSc**

*Houston Methodist Hospital  
Houston, Texas*



**KYMBERLY D.  
WATT, MD**

*Mayo Clinic  
Rochester, Minnesota*

  
**INTEGRITAS**  
COMMUNICATIONS

The Satellite Symposia content and views expressed therein are those of the sponsor and not of Digestive Disease Week®.

This activity is provided by Integritas Communications.

This activity is supported by an educational grant from Novo Nordisk Inc.